MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces that its work on NFL-102, its drug candidate for smoking cessation, has been selected for two poster presentations at major international scientific events in June 2026. 1) College on Problems of Drug Dependence (CPDD), June 13–17, 2026 The Company will present a poster